Search for: "United States v. Hatch" Results 121 - 140 of 461
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
25 Jul 2008, 2:11 am
The United States Court of Appeals for the Federal Circuit found in favor of Eisai in Aciphex patent infringement suit against Teva Pharmaceuticals and Dr. [read post]
17 Feb 2015, 5:15 am by Guest Blogger
The challenges, however, hit their own high water mark when the Supreme Court granted review in King v. [read post]
17 Jun 2016, 9:56 am by Berniard Law Firm
A recent case from the United States Fifth Circuit Court of Appeal explains how pre-existing injuries can complicate claims for maintenance and cure. [read post]
26 Aug 2008, 4:01 am
  These are the questions that have sparked a short and thought-provoking decision from SDNY Judge Marrero in United States v. [read post]
28 Sep 2016, 8:39 am by Dennis Crouch
Promega Corporation, No. 14-1538 (Whether the Federal Circuit erred in holding that supplying a single, commodity component of a multi-component invention from the United States is an infringing act under 35 U.S.C. [read post]
31 Aug 2011, 9:56 pm by Aaron Barkoff
§ 271(e)(1) states: It shall not be an act of infringement to make, use, offer to sell, or sell within the United States . . . a patented invention . . . solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use, or sale of drugs . . . . [read post]
28 Mar 2011, 7:32 am by Adam Schlossman
This morning, the Court issued orders from the Justices’ March 25 Conference, granting certiorari in one case, inviting the views of the United States in one case, and denying  all appeals made by Troy Davis. [read post]
11 Mar 2010, 6:37 am by Anna Christensen
Continuing the post-game analysis of McDonald v. [read post]
14 Oct 2007, 7:52 pm
The court agreed stating: While the Supreme Court has characterized infringement as defined in the Hatch-Waxman Act as "highly artificial," see Eli Lilly & Co. v. [read post]
10 Dec 2010, 3:16 pm by FDABlog HPM
Wyeth, Inc.], abrogated the Hatch-Waxman Amendments by allowing state tort liability for failure to warn in direct contravention of the Act’s requirement that a generic drug’s labeling be the same as the FDA-approved labeling for the listed (or branded) drug. [read post]